Skip to content
Biodatica
Start free

Hoffmann-La Roche

Duarte, California

OncologyPhase IIIListed · RHHBY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

4w agoTrial registeredJun 18, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Apr 30, 2025

    Neoplasms · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

    ClinicalTrials.gov · NCT06884618 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Mar 21, 2024

    Non-small Cell Lung Cancer (NSCLC) · TERMINATED · sponsor: Hoffmann-La Roche · A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

    ClinicalTrials.gov · NCT06267001 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Dec 5, 2023

    Carcinoma, Hepatocellular · COMPLETED · sponsor: Hoffmann-La Roche · A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

    ClinicalTrials.gov · NCT05908786 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Nov 1, 2022

    Non-Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

    ClinicalTrials.gov · NCT05170204 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Mar 18, 2022

    Rectal Neoplasms, Rectal Cancer · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

    ClinicalTrials.gov · NCT05009069 (opens the source filing in a new tab)

  6. Trial

    PHASE2 registered

    Apr 23, 2021

    Non-Small Cell Lung Cancer (NSCLC) · TERMINATED · sponsor: Hoffmann-La Roche · A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT04832854 (opens the source filing in a new tab)

  7. Trial

    PHASE1/PHASE2 registered

    Aug 12, 2020

    Follicular Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

    ClinicalTrials.gov · NCT04246086 (opens the source filing in a new tab)

  8. Trial

    PHASE3 registered

    Dec 31, 2019

    Carcinoma, Hepatocellular · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

    ClinicalTrials.gov · NCT04102098 (opens the source filing in a new tab)

  9. Trial

    Study registered

    Feb 7, 2019

    Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

    ClinicalTrials.gov · NCT03782207 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources